Pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q: A case report

Ji Hyen Lee¹, Hae Soon Kim^{1*}, Gu-Hwan Kim², and Han-Wook Yoo²

¹Department of Pediatrics, Ewha Womans University College of Medicine, Seoul, Korea

²Medical Genetics Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Pseudohypoparathyroidism type 1b (PHP 1b) is the result of end organ resistance to parathyroid hormone (PTH) in the absence of any features of Albright's hereditary osteodystrophy. There are two subtypes of PHP 1b with different genetic mechanisms. One subtype is related to a maternally derived 3kb microdeletion involving *STX 16* gene, and is inherited in an autosomal dominant mode. Familial autosomal dominant inheritance of PHP 1b is relatively rare. The other subtype is associated with more extensive loss of imprinting at the *GNAS* locus that affects at least one additional differential methylated (hypermethylation at neuroendocrine secretory protein and hypomethylation at antisense transcript and or extra-large stimulatory G protein region) without microdeletion of the *STX 16* or *AS* gene. It can be sporadic due to an imprinting defect in the *GNAS* gene. In our case, an 8-year-old girl was referred for suspected PHP with no feature of Albright hereditary osteodystrophy. Blood test results revealed hypocalcemia and hyperphosphatemia. Elevated PTH was also checked. There was no family history of endocrine or developmental problem. Her intelligence was normal, but she had inferior sociability at that time. Based on above, we diagnosed a rare case of paternal uniparental disomy of the long arm of chromosome 20 as the cause of PHP 1b by microsatellite marker test of chromosome 20.

Key words: Pseudohypoparathyroidism, Parathyroid hormone, Uniparental disomy.

Introduction

Pseudohypoparathyroidism (PHP) is the result of end-organ resistance to parathyroid hormone (PTH). PHP is characterized by hypocalcemia, hyperphosphatemia, and increased PTH levels. PHP is unusual and its exact prevalence is unclear. Identified PHP types include as type 1a, type 1b, type 1c, and type 2. PHP type 1a presents with character of Albright hereditary osteodystrophy (AHO), such as short stature, obesity, round face, subcutaneous ossifications, brachydactyly, and mental retardation. In PHP type 1a, end-organ resistance is usually not limited to the PTH

actions, but also most commonly influence thyroid stimulating hormone and, rarely, gonadotrophins and growth hormone releasing hormone [1,2]. PHP 1b typically shows no features of AHO and is characterized by renal PTH resistance but preserved PTH responsiveness in bone and other tissues resulting in lack of AHO features. Generally, PHP 1b also presents no other endocrine abnormalities, although resistance to thyroid-stimulating hormone has been rarely reported. PHP type 1c is the rarest subtype. Furthermore, It is characterized by AHO and, resistance to PTH and other hormones in face of normal *Gsα* activity.

PHP type 2 does not present with any other hormone resis-

Received: 31 January 2017, Revised: 3 April 2017, Accepted: 12 April 2017, Published: 30 June 2017

*Corresponding author: Hae Soon Kim, M.D.

Department of Pediatrics, Ewha Womans University School of Medicine, 1071 Anyangcheon-ro, Yangcheon-gu, Seoul 07985, Korea.

Tel: +82-2-2650-5569, Fax: +82-2-2650-3718, E-mail: hyesk@ewha.ac.kr

Conflict of interest: The authors declare that they do not have any conflicts of interest.

© This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/4.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

© Copyright 2017 by the Korean Society of Medical Genetics and Genomics

www.e-kjgm.org

tance and is characterized by normal urinary cyclic adenosine monophosphate (cAMP) excretion and reduced phosphate excretion. Patients with type 2 have no evidence of AHO such as acrocystosis. The underlying pathophysiology of PHP is a genetic and epigenetic change in the adenylate cyclase-stimulating G alpha protein (*GNAS*) locus, which encodes the alpha subunit of the receptor G-protein, which changed messenger action [3]. In general, patients with PHP 1b lack mutations within *GNAS* exons encoding *Gsα*, but have methylation and imprinting defects that result in the absence of maternal *Gsα* expression. We report a sporadic PHP 1b due to paternal uniparental disomy (UPD) of chromosome 20 with clinical manifestations and familial genetic analysis.

Case

An 8-year, 10-month-old girl, was carried into the emergency room due to 1-2 minute episode of convulsion without aura. She had complained for weeks of a tingling sensation in both hands and of fatigue. Her mother had recently noted unconsciousness and lack of reply to verbal interactions. She was born at 41 weeks of gestation by normal spontaneous vaginal delivery. Birth weight was 4.18 kg (>95 percentile). Development was appropriate to her age. Past history was unremarkable except for infantile asthma. She showed some difficulties in peer relationships at the elementary school level. A psychological evaluation

was not done. At the time of admission, her height was 140 cm (>97 percentile), weight was 33 kg (75-90 percentile), and body mass index was 16.8 kg/m² (50-75 percentile). Blood pressure was normal (102/66 mmHg). She had a round face. Dental characteristics included slightly enlarged pulp chamber and microdontia, but no hypoplasia. Metacarpal features of AHO were absent. Blood test results revealed hypocalcemia (ionized calcium 2.0 mg/dL, normal range 4.5-5.4 mg/dL; total calcium 4.5 mg/dL, normal range 8.2-10.5 mg/dL), hyperphosphatemia (phosphate 7.4 mg/dL, normal range 2.3-4.5 mg/dL). Elevated PTH (415 pg/mL, normal 15-65 pg/mL) was also checked. 25 Hydroxyvitamin D3 level was 20.98 ng/mL (normal range 8.0-51.9 ng/mL) and, 1,25-dihydroxyvitamin D3 was 64.14 pg/mL (normal 15-65 pg/mL). Normal levels of thyroid hormone and other pituitary hormones were evident. Electrocardiogram revealed prolonged QT (corrected QT interval 0.45 sec). Electroencephalogram revealed moderately severe diffuse cerebral dysfunction, which was more severe in the left hemisphere. Computed tomography scan revealed calcification in both basal ganglia and the right frontal lobe (Fig. 1). The patient was initially treated with intravenous calcium. Oral calcium supplement and 2 µg of 1, 25-hydroxylated vitamin D metabolite (calcitriol) were supplied when the total calcium level was 8.1 mg/dL. Her two brothers and parents did not have any phenotypic and biochemical proof of PHP. The sequence was normal. Methylation specific-multiplex ligation-dependent probe amplification (MS-MLPA; ME031 probemix; MRC-Holland, Amsterdam, The Netherlands) to detect gene dosage and methylation status in *GNAS* region showed an abnormal methylation pattern of paternal UPD (Fig. 2). To confirm patUPD20, 11 short tandem repeat markers dispersed across chromosome 20 were assessed (Fig. 3). The patient was diagnosed as paternal UPD in chromosome 20. Molecular genetic analysis for the paternal UPD in chromosome 20 in her brothers was normal.

Fig. 1. Calcifications in both basal ganglia were evident on brain computed tomography.

Discussion

PHP 1a is caused by heterozygous inactivating mutation of the *GNAS* gene that encodes the stimulatory G protein, which is necessary for the action of PTH and other hormones including thyroid stimulating hormone. The stimulatory *Gsα* that stimulates adenyl cyclase and generates cAMP is expressed by both maternal and paternal alleles of *GNAS* in most tissues. However, only the maternal allele of *GNAS* is expressed in the proximal renal tubule, thyroid, gonads, and pituitary [4].

PHP 1b is generally not related with AHO. All lack methylation

Fig. 3. Short tandem repeat marker test of chromosome 20. To identify pat uniparental disomy of the patient and her siblings, 11 markers dispersed across chromosome 20 were examined. The patient (arrow) had paternal marker sets in both alleles within a chromosome 20 region. The elder and younger brothers displayed normal segregations.

cause of PHP 1b.

Other transcripts produced by the locus are imprinted. For example, XL and A/B are paternally expressed, and NESP55 is maternally expressed [9]. These transcripts are produced by alternative first exons located upstream of exon 1 that separately splice onto exons 2–13. A noncoding antisense transcript Nespas is also exclusively paternally expressed. The promoters of the imprinted *GNAS* transcripts show differential methylation, with the imprinted allele being methylated and the active allele not being methylated. Most patients with sporadic PHP 1b have *GNAS* imprinting abnormalities involving multiple differentially methylated regions, but the molecular mechanisms underlying these *GNAS* imprinting defects remains unclear.

In our case, pat UPD of chromosome 20q12–13.32 which includes the *GNAS* locus was confirmed through the short tandem repeat marker test of chromosome 20. Several patients with PHP 1b due to pat UPD20 have been described with features including relatively high birth weight, early onset obesity, relatively tall stature, and macrocephaly [9]. In our case, elevated birth weight and tall stature were noted, but obesity and mac-

rocephaly were not evident. There was no family history of endocrine or developmental problem. Her intelligence was normal, but she had inferior sociability. We report a sporadic PHP 1b because of paternal UPD of chromosome 20 involving the long arm of chromosome 20 with clinical presentation and familial genetic analysis.

References

- Mantovani G, Spada A. Mutations in the Gs alpha gene causing hormone resistance. *Best Pract Res Clin Endocrinol Metab* 2006;20:501–13.
- Mariot V, Maupetit-Méhouas S, Sinding C, Kottler ML, Linglart A. A maternal epimutation of *GNAS* leads to Albright osteodystrophy and parathyroid hormone resistance. *J Clin Endocrinol Metab* 2008;93:661–5.
- Jin HY, Lee BH, Choi JH, Kim GH, Kim JK, Lee JH, et al. Clinical characterization and identification of two novel mutations of the *GNAS* gene in patients with pseudohypoparathyroidism and pseudopseudohypoparathyroidism. *Clin Endocrinol (Oxf)* 2011;75:207–13.

4. Levine MA, Downs RW Jr, Moses AM, Breslau NA, Marx SJ, Lasker RD, et al. Resistance to multiple hormones in patients with pseudohypoparathyroidism. Association with deficient activity of guanine nucleotide regulatory protein. *Am J Med* 1983;74:545-56.
5. Lemos MC, Thakker RV. GNAS mutations in Pseudohypoparathyroidism type 1a and related disorders. *Hum Mutat* 2015;36:11-9.
6. Bastepe M, Lane AH, Jüppner H. Paternal uniparental isodisomy of chromosome 20q--and the resulting changes in GNAS1 methylation--as a plausible cause of pseudohypoparathyroidism. *Am J Hum Genet* 2001;68:1283-9.
7. Bastepe M, Fröhlich LF, Hendy GN, Indridason OS, Josse RG, Koshiyama H, et al. Autosomal dominant pseudohypoparathyroidism type 1b is associated with a heterozygous microdeletion that likely disrupts a putative imprinting control element of GNAS. *J Clin Invest* 2003;112:1255-63.
8. Fernández-Rebollo E, Lecumberri B, Garin I, Arroyo J, Bernal-Chico A, Goñi F, et al. New mechanisms involved in paternal 20q disomy associated with pseudohypoparathyroidism. *Eur J Endocrinol* 2010;163:953-62.
9. Dixit A, Chandler KE, Lever M, Poole RL, Bullman H, Mughal MZ, et al. Pseudohypoparathyroidism type 1b due to paternal uniparental disomy of chromosome 20q. *J Clin Endocrinol Metab* 2013;98:E103-8.